natgillin/translations-raw huggingface dataset:
Additionally, all 13 serotypes met the pre-defined non-inferiority criterion for IgG GMCs (lower bound of the 97.5% CI of GMC ratio [GMR] was greater than 0.5).
Poleg tega je vseh 13 serotipov ustrezalo predhodno določenim merilom enakovrednosti za IgG GMC (spodnja meja 97,5 % IZ za razmerje GMC [GMR] je bila večja od 0,5).
Diarrhoea; vomiting (in adults aged 18 to 49 years)
diareja, bruhanje (pri odraslih, starih od 18 do 49 let)
Hypersensitivity reaction including face oedema, dyspnoea, bronchospasm
preobčutljivostna reakcija, vključno z edemom obraza, dispnejo in bronhospazmom
NB/NI - non-bacteraemic/non-invasive VT-IPD - vaccine-type invasive pneumococcal disease
NB/NI - nebakteriemijska/neinvazivna VT-IPD - invazivna pnevmokokna bolezen, povzročena z VT
For these 3 serotypes, the proportion of responders among preterm infants was significantly lower than among term infants.
Pri teh 3 serotipih je bil delež nedonošenčkov z odzivom pomembno manjši kot pri donošenčkih.
• Fever of more than 39°C; tenderness at the vaccination-site interfering with movement, redness,
• vročina, višja od 39 °C; občutljivost na mestu cepljenja, ki ovira gibanje, rdečina, zatrdlina,
As with other vaccines, the administration of Prevenar 13 should be postponed in subjects suffering from acute, severe febrile illness.
Kot pri drugih cepivih je treba tudi cepljenje s cepivom Prevenar 13 odložiti pri osebah, ki imajo hudo akutno vročinsko bolezen.
• Vomiting (for those 50 years and older); fever (for those 30 years and older)
• bruhanje (pri osebah, starih 50 let in več), vročina (pri osebah, starih 30 let in več)
For serotype 3, the percentages of Prevenar 13 recipients with serum IgG ≥ 0.35 μg/ml were 98.2% (study 006) and 63.5% (study 004).
Za serotip 3 sta bila odstotka prejemnikov cepiva Prevenar 13 s serumsko koncentracijo IgG ≥ 0,35 µg/ml 98,2 % (študija 006) in 63,5 % (študija 004).
Vomiting (in adults aged 50 years and over)
bruhanje (pri odraslih, starih 50 let in več)
Adults aged 50 years and older
Odrasli, stari 50 let in več
Children and adolescents aged 2-17 years One single dose of 0.5 ml.
Otroci in mladostniki, stari od 2 do 17 let En sam odmerek po 0,5 ml.
Data from a postmarketing clinical study evaluating the impact of prophylactic use of antipyretics (ibuprofen and paracetamol) on the immune response to Prevenar 13 suggest that administration of paracetamol concomitantly or within the same day of vaccination may reduce the immune response to Prevenar 13 after the infant series.
Podatki iz klinične študije, izvedene v obdobju trženja, ki je ocenjevala vpliv profilaktične uporabe antipiretikov (ibuprofena in paracetamola) na imunski odziv na cepivo Prevenar 13, kažejo, da lahko uporaba paracetamola sočasno ali v istem dnevu kot cepljenje zmanjša imunski odziv na cepivo Prevenar 13 pri cepljenju dojenčkov.
Higher frequency in some solicited systemic reactions was observed when Prevenar 13 was administered concomitantly with trivalent inactivated influenza vaccine (TIV) compared to TIV given alone (headache, chills, rash, decreased appetite, arthralgia, and myalgia) or Prevenar 13 given alone (headache, fatigue, chills, decreased appetite, and arthralgia).
Večja pogostnost nekaterih poročanih sistemskih reakcij je bila opažena ob sočasnem dajanju cepiva Prevenar 13 s trivalentnim inaktiviranim cepivom proti gripi (TIV) v primerjavi s samostojno danim cepivom TIV (glavobol, mrzlica, izpuščaj, zmanjšan apetit, artralgija in mialgija) ali samostojno danim cepivom Prevenar 13 (glavobol, utrujenost, mrzlica, zmanjšan apetit in artralgija).
In a similar analysis, hospitalisations and ambulatory visits for all-cause pneumonia were reduced by 52.4 % and 41.1 %, respectively.
V podobni analizi so se sprejemi na zdravljenje v bolnišnico zaradi pljučnice ne glede na vzrok zmanjšali za 52,4 %, ambulantni pregledi pa za 41,1 %.
Infants aged 7-11 months
Dojenčki, stari od 7 do 11 mesecev
In clinical studies, the safety profile of Prevenar 13 was similar to Prevenar.
V kliničnih študijah je bil varnostni profil cepiva Prevenar 13 podoben kot pri cepivu Prevenar.
Immunogenicity and safety of Prevenar 13 has been demonstrated in adults aged 18 years and older including those previously vaccinated with a pneumococcal polysaccharide vaccine.
Imunogenost in varnost cepiva Prevenar 13 so dokazali pri odraslih, starih 18 let in več, vključno s tistimi, ki so bili predhodno cepljeni s pnevmokoknim polisaharidnim cepivom.
Children younger than 2 years old should receive the appropriate-for-age Prevenar 13 vaccination series (see section 4.2).
Pri otrocih, mlajših od 2 let, je treba uporabiti starosti primerno shemo cepljenja s cepivom Prevenar 13 (glejte poglavje 4.2).
Immune responses to serotype 6A were statistically significantly greater following vaccination with Prevenar 13 than after 23-valent pneumococcal polysaccharide vaccine.
Imunski odzivi na serotip 6A so bili statistično pomembno večji po cepljenju s cepivom Prevenar 13 kot po cepljenju s 23-valentnim pnevmokoknim polisaharidnim cepivom.
hardness, swelling at the vaccination-site of 2.5 cm -7.0 cm (after the initial course of injections)
oteklina na mestu cepljenja s premerom 2,5 cm-7 cm (po začetni shemi injekcij)
Additional information in special populations
Dodatne informacije o posebnih populacijah
Administer the entire dose.
Aplicirajte celotni odmerek.
Children < 2 years of age.
Otroci, mlajši od 2 let.
Vaccine serotypes: 76% All serotypes: 38%
Serotipi cepiva: 76 % Vsi serotipi: 38 %
Overall, no significant differences in frequencies of adverse reactions were seen when Prevenar 13 was given to adults previously vaccinated with the pneumococcal polysaccharide vaccine.
V celoti ni bilo pomembnih razlik v pogostnosti neželenih učinkov, če so cepivo Prevenar 13 dali odraslim, ki so bili predhodno cepljeni s pnevmokoknim polisaharidnim cepivom.
The proportion of infants achieving a pneumococcal anti-capsular polysaccharide IgG concentration ≥ 0.35 g/ml one month after the second dose ranged from 79.6% to 98.5% across 11 of the 13 vaccine serotypes.
Delež dojenčkov s koncentracijo pnevmokoknih antikapsularnih polisaharidnih IgG ≥ 0,35 μg/ml en mesec po drugem odmerku se je gibal med 79,6 % in 98,5 % pri 11 od 13 serotipov cepiva.
1 dose (0.5 ml) contains 0.125 mg aluminium.
En odmerek (0,5 ml) vsebuje 0,125 mg aluminija.
First episode of confirmed VT pneumococcal CAP
Prva epizoda potrjene VT-pnevmokokne CAP
• has any bleeding problems or bruises easily.
• kakršnekoli težave s krvavitvami ali hitrim pojavom modric.
Subsequently, four years following the switch to Prevenar 13, the additional reduction in incidence of IPD due to the 7 serotypes in Prevenar ranged from 76% in children less than 2 years of age to 91% in children 5-14 years of age.
Nato se je 4 leta po prehodu na cepivo Prevenar 13 incidenca IPD, ki jo povzroča 7 serotipov v cepivu Prevenar, dodatno zmanjšala od 76 % pri otrocih, mlajših od 2 let, do 91 % pri otrocih, starih od 5 do 14 let.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'.
To cepivo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni 'brez natrija'.
≥65 years of age
Stari ≥ 65 let
If your child should become unresponsive or experience seizures (fits) after the vaccination, please contact your doctor immediately.
Če se po cepljenju vaš otrok preneha odzivati ali doživi epileptični napad, prosimo nemudoma obvestite zdravnika.
Antibody responses to booster doses following two-dose or three-dose infant primary series were comparable for all 13 vaccine serotypes.
Odzivi protiteles na obnovitvene odmerke po osnovnem cepljenju z dvema ali tremi odmerki za dojenčke so bili primerljivi pri vseh 13 serotipih cepiva.
• children from 6 weeks to 17 years to help protect against diseases such as: meningitis (inflammation around the brain), sepsis or bacteraemia (bacteria in the blood stream), pneumonia (lung infection) and ear infections
• otrok, starih od 6 tednov do 17 let, za zaščito pred boleznimi, kot so: meningitis (vnetje možganskih ovojnic), sepsa ali bakteriemija (prisotnost bakterij v krvi), pljučnica (okužba pljuč) in okužbe ušesa;
Safety and immunogenicity of Prevenar 13 containing the preservative 2-PE (presented in a multidose container) given to healthy infants at 8, 12 and 16 weeks of age were compared to those of Prevenar 13 without added preservative (250 infants per group).
Varnost in imunogenost cepiva Prevenar 13 s konzervansom 2-PE (pakiranje v večodmernem vsebniku), uporabljenega pri zdravih dojenčkih v 8., 12. in 16. tednu starosti, so primerjali z varnostjo in imunogenostjo cepiva Prevenar 13 brez dodanega konzervansa (250 dojenčkov v vsaki skupini).
Study of Prevenar 13 containing the preservative 2-phenoxyethanol (2-PE):
Študija cepiva Prevenar 13, ki vsebuje konzervans 2-fenoksietanol (2-PE):
50-59 Years N=350-384
50-59 let n = 350-384
In individuals with an haematopoietic stem cell transplant (HSCT), the recommended immunisation series consists of four doses of Prevenar 13, each of 0.5 ml.
Pri posameznikih s presadkom hematopoetskih matičnih celic (HSCT - haematopoietic stem cell transplant) priporočeno shemo cepljenja sestavljajo štirje odmerki cepiva Prevenar 13 po 0,5 ml.
Multidose containers:
Večodmerni vsebniki:
Do not use this medicine after the expiry date which is stated on the carton and label after EXP.
Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki poleg oznake EXP. Rok uporabnosti cepiva se izteče na zadnji dan navedenega meseca.
Manufacturer responsible for batch release: Wyeth Pharmaceuticals New Lane
Izdelovalec, odgovoren za sproščanje serij: Wyeth Pharmaceuticals New Lane
It is important to follow the instructions from the doctor, pharmacist, or nurse so that your child completes the course of injections.
Pomembno je, da upoštevate navodila zdravnika, farmacevta ali medicinske sestre, tako da otrok prejme vse predvidene odmerke cepiva v predvidenem času.
Data published by Public Health England showed that, four years after the introduction of Prevenar as a two dose primary infant series with booster dose in the second year of life and with a 94% vaccine uptake, there was a 98% (95% CI 95; 99) reduction in disease caused by the 7 vaccine serotypes in England and Wales.
Podatki, ki jih je objavila ustanova Public Health England, so pokazali, da so v Angliji in Walesu štiri leta po uvedbi cepiva Prevenar z osnovno shemo z dvema odmerkoma za dojenčke ter obnovitvenim odmerkom v drugem letu življenja in 94 % privzemom cepiva ugotovili 98 % (95 % IZ, 95-99) zmanjšanje bolezni, ki jo povzroča 7 serotipov cepiva.
• adults aged 18 years and older to help prevent disease such as: pneumonia (lung infection), sepsis or bacteraemia (bacteria in the blood stream) and meningitis (inflammation around the brain), caused by 13 types of the bacteria Streptococcus pneumoniae.
• odraslih, starih 18 let ali več, za zaščito pred boleznimi, kot so: pljučnica (okužba pljuč), sepsa ali bakteriemija (prisotnost bakterij v krvi) in meningitis (vnetje možganskih ovojnic), ki jih povzroča 13 tipov bakterije Streptococcus pneumoniae.
Concomitant administration of Prevenar 13 and 23-valent pneumococcal polysaccharide vaccine has not been studied.
Sočasnega dajanja cepiva Prevenar 13 in 23-valentnega pnevmokoknega polisaharidnega cepiva niso raziskali.
Single-dose vials:
Enoodmerne viale:
Antibody persistence and immunological memory were evaluated in a study in healthy children who received a single dose of Prevenar 13 at least 2 years after they had been previously immunised with either 4 doses of Prevenar, a 3-dose infant series of Prevenar followed by Prevenar 13 at 12 months of age, or 4 doses of Prevenar 13.
Trajanje prisotnosti protiteles in imunološki spomin so ocenjevali v študiji pri zdravih otrocih, ki so prejeli enkraten odmerek cepiva Prevenar 13 najmanj 2 leti po tem, ko so bili predhodno imunizirani bodisi s 4 odmerki cepiva Prevenar bodisi 3 odmerki cepiva Prevenar za otroke, čemur je sledilo dajanje cepiva Prevenar 13 pri starosti 12 mesecev, bodisi s 4 odmerki cepiva Prevenar 13.
NCKP: Acute Otitis Media (AOM) Total episodes
NCKP: akutno vnetje srednjega ušesa Vse epizode
Regardless of prior pneumococcal vaccination status, if the use of 23-valent pneumococcal polysaccharide vaccine is considered appropriate, Prevenar 13 should be given first (see sections 4.5 and 5.1).
Ne glede na to, ali je bil bolnik predhodno že cepljen proti pnevmokokom, je v primeru priporočljive uporabe 23-valentnega pnevmokoknega polisaharidnega cepiva najprej treba dati cepivo Prevenar 13 (glejte poglavji 4.5 in 5.1).
• Fever (for those 18 to 29 years of age)
• vročina (pri osebah, starih od 18 do 29 let)
The clinical relevance of these differences is not known.
Klinični pomen teh razlik ni znan.
The use of pneumococcal conjugate vaccine does not replace the use of 23-valent pneumococcal polysaccharide vaccines in children ≥ 2 years of age with conditions (such as sickle cell disease, asplenia, HIV infection, chronic illness, or those who are immuno-compromised) placing them at higher risk for invasive disease due to Streptococcus pneumoniae.
Uporaba konjugiranega cepiva proti pnevmokokom ne nadomesti uporabe 23-valentnega pnevmokoknega polisaharidnega cepiva pri otrocih, starih  2 leti, s stanji, kot so srpastocelična anemija, asplenija, okužba z virusom HIV, kronične bolezni ali imunska kompromitiranost, zaradi katerih obstaja večje tveganje za invazivno bolezen, ki jo povzroča bakterija Streptococcus pneumoniae.
One of the 7 studies included a group of adults (n=899) ranging from 18 to 49 years who received Prevenar 13 and who were not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Ena od sedmih študij je vključevala skupino odraslih (n = 899), starih od 18 do 49 let, ki so prejeli cepivo Prevenar 13 in niso bili predhodno cepljeni s 23-valentnim pnevmokoknim polisaharidnim cepivom.
Prevenar 13 is estimated to cover over 90% of serotypes causing antimicrobial-resistant IPD.
Ocenjujejo, da cepivo Prevenar 13 pokriva več kot 90 % serotipov, ki povzročajo proti protimikrobnim zdravilom odporne invazivne pnevmokokne bolezni.
A significant increase was seen in the concentrations of antibodies against the seven serotypes after the polysaccharide vaccination, suggesting that immunological memory was well established.
Po polisaharidnem cepljenju so opazili pomembno povečanje koncentracij protiteles proti sedmim serotipom, kar kaže, da je bil imunološki spomin dobro vzpostavljen.
In adults, an antibody threshold of serotype-specific pneumococcal polysaccharide IgG binding antibody concentration associated with protection has not been defined.
Prag koncentracije serotipno specifičnih pnevmokoknih polisaharidnih protiteles IgG, povezan z zaščito, pri odraslih ni bil določen.
The risk for CAP and IPD in adults also increases with chronic underlying medical conditions, specifically, anatomical or functional asplenia, diabetes mellitus, asthma, chronic cardiovascular, pulmonary, kidney or liver disease, and it is highest in those who are immune-suppressed such as those with malignant haematological diseases or HIV infection.
Tveganje za CAP in IPD pri odraslih se poveča tudi v prisotnosti kroničnih osnovnih bolezni, zlasti anatomske ali funkcionalne asplenije, sladkorne bolezni, astme, kronične kardiovaskularne, pulmonalne, ledvične ali jetrne bolezni, največje pa je pri bolnikih z imunosupresijo, kot so bolniki z malignimi hematološkimi boleznimi ali okužbo s HIV.
Total episodes
Vse epizode
2, 4, + 12 months
2., 4., + 12. mesec
Smaller proportions of infants achieved this antibody concentration threshold for serotype 6B (27.9% to 57.3%) and 23F (55.8% to 68.1%) for all studies using a 2, 4 month regimen, compared to 58.4% for serotype 6B and 68.6% for 23F for a study using a 3, 5 month regimen.
Manjši delež dojenčkov je dosegel ta prag koncentracije protiteles za serotip 6B (27,9 % do 57,3 %) in 23F (55,8 % do 68,1 %) v vseh študijah, v katerih so uporabili 2, 4-mesečno shemo cepljenja, v primerjavi z 58,4 % za serotip 6B in 68,6 % za 23F v študiji, v kateri so uporabili 3, 5-mesečno shemo cepljenja.
The preferred sites are the anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in children and adults.
Pri dojenčkih je najprimernejše mesto injiciranja anterolateralni predel stegna (mišica vastus lateralis), pri otrocih in odraslih pa deltoidna mišica nadlakti.
• A rash causing itchy red blotches (erythema multiforme)
• izpuščaj, ki povzroča srbeče rdeče lise (multiformni eritem)
Immune responses were assessed in 231-255 evaluable subjects approximately 1 month after each dose of Prevenar 13.
Imunski odziv so ocenili pri 231-255 ocenljivih preskušancih približno 1 mesec po vsakem odmerku cepiva Prevenar 13.
VE (%) (95.2% CI)
UC (%) (95,2 % IZ)
Safety and immunogenicity of Prevenar 13 given at 2, 3, 4 and 12 months was assessed in approximately 100 prematurely born infants (mean Estimated Gestational Age [EGA], 31 weeks; range, 26 to 36 weeks) and compared with approximately 100 infants born at term (mean EGA, 39 weeks; range, 37 to 42 weeks).
Varnost in imunogenost cepiva Prevenar 13, uporabljenega pri 2, 3, 4 in 12 mesecih, so ocenili pri približno 100 nedonošenčkih (povprečna ocenjena gestacijska starost 31 tednov, razpon od 26 do 36 tednov) in ju primerjali s približno 100 donošenčki (povprečna ocenjena gestacijska starost 39 tednov, razpon od 37 do 42 tednov).
Table 3: Summary of efficacy of 7-valent Prevenar
Preglednica 3: Povzetek učinkovitosti 7-valentnega cepiva Prevenar
restless sleep; tenderness at the vaccination-site interfering with movement
zaspanost, nemirno spanje, občutljivost na mestu cepljenja, ki ovira gibanje
The single dose of Prevenar 13, in children approximately 3.4 years of age regardless of previous vaccination history with Prevenar or Prevenar 13, induced a robust antibody response for both the 7 common serotypes and the 6 additional serotypes in Prevenar 13.
Enkraten odmerek cepiva Prevenar 13 je pri otrocih v starosti približno 3,4 leta, ne glede na predhodna cepljenja s cepivom Prevenar ali Prevenar 13, povzročil močan odziv protiteles tako za 7 skupnih serotipov kot za 6 dodatnih serotipov pri cepivu Prevenar 13.
After the second and third dose of Prevenar 13, immune responses were similar or higher than those after the first dose.
Po drugem in tretjem odmerku cepiva Prevenar 13 je bil imunski odziv podoben ali večji kot po prvem odmerku.
For children aged from 7 months to 5 years, age appropriate catch-up immunisation schedules (as described in section 4.2) result in levels of anti-capsular polysaccharide IgG antibody responses to each of the 13 serotypes that are at least comparable to those of a three-dose primary series in infants.
Pri otrocih, starih od 7 mesecev do 5 let, starosti primerne imunizacijske sheme za dohitevanje (opisane v poglavju 4.2) povzročijo ravni odzivov antikapsularnih polisaharidnih protiteles IgG na vsakega od 13 serotipov, ki so vsaj primerljive s tistimi, ki jih dosežemo po osnovnem cepljenju dojenčkov s tremi odmerki.
Prevenar 13 can be given concomitantly with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, acellular or whole cell pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B (see section 4.4 for guidance on Infanrix hexa), meningococcal serogroup C, measles, mumps, rubella, varicella and rotavirus vaccine.
Cepivo Prevenar 13 se lahko uporablja skupaj s katerimkoli od naslednjih antigenov, bodisi v obliki monovalentnih ali kombiniranih cepiv: s cepivom proti davici, tetanusu, z acelularnim cepivom proti oslovskemu kašlju ali s cepivom proti oslovskemu kašlju s celimi celicami, s cepivom proti Haemophilus influenzae tipa b, z inaktiviranim cepivom proti poliomielitisu, s cepivom proti hepatitisu B (glejte poglavje 4.4 za navodila glede cepiva Infanrix hexa), s cepivom proti meningokokom serološke skupine C, s cepivom proti ošpicam, mumpsu, rdečkam, noricam in rotavirusom.
For those events specifically identified as pneumococcal pneumonia, the observed reductions in hospitalisations and ambulatory visits were 57.6 % and 46.9 %, respectively, in children younger than 2 years of age, compared with a pre-licensure baseline (2004 vs. 1997-99).
Za tiste dogodke, ki so bili posebej identificirani kot pnevmokokna pljučnica, so se pri otrocih, mlajših od 2 let, hospitalizacije in ambulantni obiski zmanjšali za 57,6 % oziroma 46,9 % v primerjavi z izhodiščem pred odobritvijo cepiva (2004 proti 1997-99).
Following the introduction of Prevenar and subsequently Prevenar 13 there was a decline in incidence from 2.1 to 0.1 cases per 1000 children (95%) for the Prevenar serotypes plus serotype 6A and a decline in incidence from 0.9 to 0.1 cases per 1000 children (89%) for the additional serotypes 1, 3, 5, 7F, and 19A in Prevenar 13.
Po uvedbi cepiva Prevenar in pozneje cepiva Prevenar 13 so ugotovili zmanjšanje incidence z 2,1 na 0,1 primera na 1.000 otrok (95 %) za serotipe cepiva Prevenar in serotip 6A ter zmanjšanje incidence z 0,9 na 0,1 primera na 1.000 otrok (89 %) za dodatne serotipe 1, 3, 5, 7F in 19A, ki jih vsebuje cepivo Prevenar 13.
Responses to the booster dose administered at 12 months were unaffected.
Odzivi na obnovitveni odmerek, dan pri 12 mesecih starosti, so bili nespremenjeni.
Immunogenicity studies in adults ≥18 years and the elderly
Študije imunogenosti pri odraslih, starih 18 let in več, ter starejših
Recurrent AOM (3 episodes in 6 months, or 4 episodes in 1 year) Recurrent AOM (5 episodes in 6 months, or 6 episodes in 1 year) Tympanostomy tube placement
Ponavljajoča se akutna vnetja srednjega ušesa (3 epizode v 6 mesecih ali 4 epizode v 1 letu)
An open label single arm study in France, Italy, UK, US, Lebanon, Egypt and Saudi Arabia with 2 doses of Prevenar 13 given 6 months apart was conducted in 158 children and adolescents ≥ 6 to < 18 years of age with sickle cell disease who were previously vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine at least 6 months prior to enrollment.
V Franciji, Italiji, Veliki Britaniji, ZDA, Libanonu, Egiptu in Savdski Arabiji so opravili odprto študijo z eno skupino z 2 odmerkoma cepiva Prevenar 13 z razmikom 6 mesecev pri 158 otrocih in mladostnikih ≥ 6 do < 18 let s srpastocelično anemijo, ki so jih predhodno cepili z enim ali več odmerki 23-valentnega pnevmokoknega polisaharidnega cepiva vsaj 6 mesecev pred vključitvijo v študijo.
• Redness, swelling, or hardness at the vaccination-site of more than 7 cm; crying
• rdečina, oteklina ali zatrdlina na mestu cepljenja, večja od 7 cm; jok
One year after the second dose, antibody levels measured by both IgG GMCs and OPA GMTs were higher than levels prior to the first dose of Prevenar 13, except for the IgG GMCs for serotypes 3 and 5 that were numerically similar.
Eno leto po drugem odmerku so bile ravni protiteles, izmerjene z IgG GMC in OPA GMT, višje kot ravni pred prvim odmerkom cepiva Prevenar 13, razen pri IgG GMC za serotipa 3 in 5, ki sta bila številčno podobna.
Pack of 1, 10 and 50 pre-filled syringe, with or without needle - WITH BLUE BOX
Pakiranje po 1, 10 in 50 napolnjenih injekcijskih brizg, z injekcijsko iglo ali brez nje - Z MODRIM OKENCEM
Prevenar 13 may be given to adults aged 50 years and older at the same time as the trivalent or quadrivalent inactivated influenza vaccine.
Cepivo Prevenar 13 se lahko aplicira odraslim, starim 50 let in več, sočasno s trivalentnim ali štirivalentnim inaktiviranim cepivom proti gripi.
The interval between the 13-valent pneumococcal conjugate vaccine (Prevenar 13) and the 23-valent pneumococcal polysaccharide vaccine should not be less than 8 weeks.
Časovni presledek med cepljenjem s 13-valentnim konjugiranim cepivom proti pnevmokokom (Prevenar 13) in 23-valentnim pnevmokoknim polisaharidnim cepivom mora biti vsaj 8 tednov.
• Headaches
• glavoboli